Hubei Jumpcan Pharmaceutical (600566.SH): plans to buy back 25 million to 50 million yuan of company shares.
On July 22, Gelunhui reported that Hubei Jumpcan Pharmaceutical (600566.SH) intends to repurchase company shares for a total amount not less than 25 million yuan and not exceeding 50 million yuan. The repurchase price shall not exceed 48 yuan per share, and it will be used to implement employee stock ownership plans or stock-based incentives.
Hubei Jumpcan Pharmaceutical (600566.SH): The repurchase period has expired and the company has repurchased 0.11% of its own shares.
On July 4th, Gelonhui reported that Hubei Jumpcan Pharmaceutical (600566.SH) completed the buyback through centralized bidding trading of the company's stock repurchase special securities account, accumulating 1,051,700 shares of the company's stock, accounting for 0.11% of the current total share capital of the company, at a maximum buyback price of 34.82 yuan per share, a minimum price of 27.19 yuan per share, and an average buyback price of 28.64 yuan per share, using a total amount of funds of 30,123,799.88 yuan (excluding transaction costs), as of July 3, 2024, when the buyback deadline expires.
Hubei Jumpcan Pharmaceutical Obtains Drug Registration for Antibiotic Injection; Shares Down 3%
Hubei Jumpcan Pharmaceutical (SHA:600566) received the drug registration certificate for its antibiotic drug, levofloxacin sodium chloride injection, from the State Drug Administration. The company sa
Hubei Jumpcan Pharmaceutical (600566.SH): Levofloxacin Sodium Chloride Injection Obtains Pharmaceutical Registration Certificate.
On June 26, Gelunhui reported that Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Jumpcan Pharmaceutical Group Co., Ltd. (referred to as 'Jumpcan Limited') received the Drug Registration Certificate for Levofloxacin Sodium Chloride Injection issued and approved by the National Medical Products Administration. Levofloxacin is the levorotatory form of ofloxacin, with its antibacterial activity about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase and inhibit bacterial DNA replication.
Hubei Jumpcan Pharmaceutical Gets Drug Registration Certificate for Allergy Drug; Shares Slide 3%
Hubei Jumpcan Pharmaceutical (SHA:600566) received the drug registration certificate for the fexofenadine hydrochloride dry suspension from the State Drug Administration, according to a Thursday filin
Jichuan Pharmaceutical (600566.SH): Fexofenadine hydrochloride dry suspension obtained drug registration certificate
On June 19th, Ge Long Hui reported that Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Hubei Jumpcan Pharmaceutical Group Co., Ltd (referred to as Jumpcan Limited), has received the Drug Registration Certificate for the Hydrochloride Fexofenadine Hydrochloride Dry Suspension, approved and issued by the National Medical Products Administration. Hydrochloride fexofenadine hydrochloride is a second-generation H1 receptor antagonist that can selectively block H1 receptors. It is the main active metabolite of terfenadine and has anti-histamine activity.
Is It Smart To Buy Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) Before It Goes Ex-Dividend?
Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) is about to trade ex-dividend in the next 3 days. The ex-dividend date is one business day before a company's record date, which is the date on wh
Jumpcan Pharmaceutical Adjusts Repurchase Price Cap After Annual Share Distribution
Hubei Jumpcan Pharmaceutical (SHA:600566) has adjusted the upper limit of its repurchase price cap following the implementation of its 2023 annual share distribution, according to a Tuesday filing on
Hubei Jumpcan Pharmaceutical (600566.SH) plans to distribute CNY 13 per 10 shares in 2023. The ex-dividend date is June 17th.
Hubei Jumpcan Pharmaceutical (600566.SH) announced that it plans to distribute cash to all shareholders in 2023, at a ratio of 10 shares per share...
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Low P/E No Reason For Excitement
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 30x, you may consider Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) as a highly attractive investment
Hubei Jumpcan Pharmaceutical (600566.SH): Has repurchased a total of 961,700 shares.
On June 4th, Gelonhui reported that Hubei Jumpcan Pharmaceutical (600566.SH) has cumulatively repurchased 961,700 shares through centralized bidding trading as of May 31, 2024, accounting for 0.10% of the total share capital of the company. The highest purchase price was 30.97 yuan/share, and the lowest purchase price was 27.19 yuan/share. The total amount paid was RMB 27,094,699.88 (excluding transaction fees).
Is Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Recent Stock Performance Tethered To Its Strong Fundamentals?
Hubei Jumpcan Pharmaceutical's (SHSE:600566) stock is up by a considerable 11% over the past three months. Since the market usually pay for a company's long-term fundamentals, we decided to study th
Here's Why We Think Hubei Jumpcan Pharmaceutical (SHSE:600566) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Jichuan Pharmaceutical (600566.SH): Net profit of 845 million yuan in the first quarter increased 24.90% year-on-year
Gelonghui, April 19: Jichuan Pharmaceutical (600566.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 2,403 billion yuan, an increase of 0.60%; net profit attributable to shareholders of listed companies of 845 million yuan, an increase of 24.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 726 million yuan, an increase of 19.83% year on year; basic earnings per share were 0.923 yuan.
These 4 Measures Indicate That Hubei Jumpcan Pharmaceutical (SHSE:600566) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Jichuan Pharmaceutical (600566.SH): Proposed 2024 Employee Stock Ownership Plan
Gelonghui, April 9, 丨 Jichuan Pharmaceutical (600566.SH) announced the 2024 employee stock ownership plan. The total number of employees participating in the current employee stock ownership plan is no more than 70, and the scale of setting up the employee stock ownership plan is no more than 14.3055 million yuan. The price of the employee's shareholding plan to buy back shares is 37.78 yuan/share.
Jichuan Pharmaceutical (600566.SH): Net profit increased 30.04% year-on-year in 2023, and plans to distribute 13 yuan to 10 shares
Gelonghui, April 9, 丨 Jichuan Pharmaceutical (600566.SH) released its 2023 annual report, with operating revenue of 9.65 billion yuan, up 7.32% year on year, net profit of 2.82 billion yuan, up 30.04% year on year, after deducting non-net profit of 2.69 billion yuan, up 32.72% year on year, with basic earnings of 3.08 yuan per share. A cash dividend of 13 yuan is distributed to all shareholders for every 10 shares.
Zhongtai Securities: Q1 results are about to be implemented, gradually focus on the pharmaceutical sector and individual stocks with improved Q2 performance
Zhongtai Securities said that at present, the overall market is still at a relative bottom. After experiencing a long-term correction, the pharmaceutical sector is also at multiple bottoms in terms of fundamentals, policies, and capital, and is firmly optimistic about the pharmaceutical sector market throughout the year.
Zheshang Securities: An important new business format that is currently breaking the pharmaceutical market, the future of the CSO sector may support the growth of relevant industry targets, etc.
The Zhitong Finance App learned that Zheshang Securities released a research report stating that profitability is related to product IP ownership, product development stage, and CSO's empowerment of products. In the future, the profitability of the CSO business is expected to continue to improve as the product structure gradually matures and the proportion of its own IP products increases. At this stage, based on judging the current macroeconomic environment and the direction of continuous deepening of medical reform, the CSO sector is an important new business format for breaking the current pharmaceutical market. Changes in business trends may support the growth and profitability of the internal standards of the business format to exceed market expectations. Recommended attention: It has proven its own brand marketing capabilities, and has mature sales channels and capabilities
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Top Owners Are Private Companies With 57% Stake, While 27% Is Held by Individual Investors
Key Insights Significant control over Hubei Jumpcan Pharmaceutical by private companies implies that the general public has more power to influence management and governance-related decisions 56% of
No Data